Promising Phase II data and a flurry of deal-making indicate that bispecific platform technologies are about to take antibodies to the next level.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair
Nature Communications Open Access 27 May 2016
-
A Dual Target-directed Agent against Interleukin-6 Receptor and Tumor Necrosis Factor α ameliorates experimental arthritis
Scientific Reports Open Access 04 February 2016
-
Ganglioside GD2-specific trifunctional surrogate antibody Surek demonstrates therapeutic activity in a mouse melanoma model
Journal of Translational Medicine Open Access 07 November 2012
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Holmes, D. Buy buy bispecific antibodies. Nat Rev Drug Discov 10, 798–800 (2011). https://doi.org/10.1038/nrd3581
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3581
This article is cited by
-
Advances in antibody engineering for rheumatic diseases
Nature Reviews Rheumatology (2019)
-
A Dual Target-directed Agent against Interleukin-6 Receptor and Tumor Necrosis Factor α ameliorates experimental arthritis
Scientific Reports (2016)
-
A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair
Nature Communications (2016)
-
Simulations of site-specific target-mediated pharmacokinetic models for guiding the development of bispecific antibodies
Journal of Pharmacokinetics and Pharmacodynamics (2015)
-
Autonomous molecular cascades for evaluation of cell surfaces
Nature Nanotechnology (2013)